Protokinetix Inc.

PKTX

$0.01May 03, 2021May 01, 2026
Health CareBiotechnology$2M
MVM
+$0.0M
PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Chart Start
$0.22
2021
Since 2021
-97.5%
vs SPY +72.3%
All-time High
$0.26 · May 2021
-97.9% from peak
MVM Rank
#276 of 589
Biotechnology
Reaction Win Rate
20%
2 of 10 events

Protokinetix Inc. has returned -97.5% from $0.22 since 2021, trailing SPY's +72.3% over the same period. The stock hit an all-time high of $0.26 in May 2021 and is currently 97.9% below that level. Of 10 tracked news events, 20% produced a positive market-adjusted return.

How to use this page
1Company Research Snapshot

Expand to read Wikipedia-sourced background on the company. Click any linked term to explore it inline — no page reload.

2Company Q&A

Common questions answered from real data: performance vs SPY, market cap, profitability, CEO, dividends, and more.

3News & Events

Every dot on the chart is a news event. The return shown is market-adjusted (vs SPY). Green = stock outperformed. Red = underperformed. Dot size = magnitude of reaction.

Show ▼
Company Q&AShow ▼
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2025-11-17-18.8%executiveSEC EDGARPKTX 8-K: 5.02, 7.01 (SEC Filing)
2022-03-21-17.1%executiveSEC EDGARPKTX 8-K: 3.02, 5.02 (SEC Filing)
2023-02-01-12.9%newsSEC EDGARPKTX 8-K: 8.01 (SEC Filing)
2022-12-13+9.9%newsSEC EDGARPKTX 8-K: 3.02 and 5.02 (SEC Filing)
2022-02-14-7.9%executiveSEC EDGARPKTX 8-K: 3.03, 5.02, 5.03, 5.07, 7.01, 8.01 (SEC Filing)
2023-01-04-5.6%newsSEC EDGARPKTX 8-K: 3.02 and (SEC Filing)
2025-04-25-4.8%newsStock TitanPKTX Stock Price, News & Analysis | Protokinetix - Stock Titan
2026-03-31-3.7%newsStock TitanProtokinetix (PKTX) submits Form 12b-25, 10-K delayed 15 days - Stock Titan
2023-02-19+2.3%newsGuruFocusLachlan Grant Young Net Worth (2026) - GuruFocus
2021-05-12-0.0%newsSeeking AlphaProtoKinetix and IQVIA partner to support development of eye treatment
tickerdossier.comtickerdossier.substack.com